Portola Pharmaceuticals Inc (NASDAQ:PTLA) Institutional Investors Sentiment Index Up in 2019 Q1

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Sentiment for Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) institutional sentiment increased to 2.04 in Q1 2019. Its up 1.14, from 0.9 in 2018Q4. The ratio is positive, as 100 investment professionals opened new and increased positions, while 49 sold and decreased their stakes in Portola Pharmaceuticals Inc. The investment professionals in our partner’s database now hold: 61.89 million shares, down from 63.72 million shares in 2018Q4. Also, the number of investment professionals holding Portola Pharmaceuticals Inc in their top 10 positions increased from 3 to 4 for an increase of 1. Sold All: 9 Reduced: 40 Increased: 54 New Position: 46.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.09 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

The stock decreased 0.23% or $0.07 during the last trading session, reaching $30.52. About 1.75 million shares traded or 55.60% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 24.87% since August 15, 2018 and is downtrending. It has underperformed by 24.87% the S&P500.

Fernwood Investment Management Llc holds 7.16% of its portfolio in Portola Pharmaceuticals, Inc. for 387,011 shares. Cadian Capital Management Lp owns 3.97 million shares or 5.38% of their US portfolio. Moreover, Highland Capital Management Lp has 3.37% invested in the company for 1.56 million shares. The Florida-based Harvey Capital Management Inc has invested 2.65% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 609,357 shares.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Ratings analysis reveals 75% of Portola Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Portola Pharma, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3500 while the high is $50. The stock’s average target of $40.50 is 32.70% above today’s ($30.52) share price. PTLA was included in 9 notes of analysts from March 4, 2019. Credit Suisse reinitiated it with “Neutral” rating and $3500 target in Monday, August 5 report. Oppenheimer maintained the shares of PTLA in report on Monday, March 4 with “Buy” rating. On Monday, March 4 the stock rating was maintained by Credit Suisse with “Hold”. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Citigroup on Monday, March 4. On Monday, March 4 the stock rating was maintained by Morgan Stanley with “Buy”.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Nasdaq.com which released: “Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release – Nasdaq” on May 01, 2019, also Prnewswire.com with their article: “Portola Launches European Sales of Ondexxya┬« (Andexanet Alfa) with First Orders in Europe – PRNewswire” published on August 06, 2019, Globenewswire.com published: “Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 – GlobeNewswire” on April 17, 2019. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Nasdaq.com and their article: “Noteworthy Wednesday Option Activity: OLED, PTLA, TWLO – Nasdaq” published on April 24, 2019 as well as Benzinga.com‘s news article titled: “8 Stocks Moving In Monday’s After-Hours Session – Benzinga” with publication date: August 12, 2019.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.